Dr. Hershman on Adherence to Longer Hormonal Therapy

Video

In Partnership With:

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Recent studies have further verified the benefit for patients with breast cancer to stay on tamoxifen for 10 years as opposed to 5 years. As a result, the oncology community needs to consider issues related to adherence and compliance.

Researchers have found that at the end of 5 years of tamoxifen, only about 50% of patients take the medication greater than 80% of the time. Researchers also saw that about 25-30% of patients discontinued medication completely, while 25% took it intermittently.

These patients are so far out from their diagnosis, Hershman says, so physicians need to think about how to keep these patients engaged in treatment.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD